Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences has revised the expected timetable for using the remaining proceeds from its 2022 issuance of A shares, primarily earmarked for innovative drug R&D projects and the construction of its Shanghai biotech headquarters and R&D base. As of 30 June 2025, RMB 1.181 billion of the RMB 3.745 billion raised had been utilized, and the company now expects to fully deploy the outstanding funds for innovative drug R&D by 31 December 2028 and for the headquarters and R&D base project by 30 June 2026, reflecting adjustments driven by actual project progress, changes in certain sub-projects, and clinical development timelines while maintaining the original investment scope, use and implementing entities.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$21.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative drugs, with a strong emphasis on R&D pipelines and related infrastructure such as its biotech headquarters and R&D base in Shanghai.
Average Trading Volume: 3,515,688
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.58B
For detailed information about 1877 stock, go to TipRanks’ Stock Analysis page.